EDMONTON, Nov. 26 /CNW/ - Isotechnika Inc. announced today that the
Company has been issued Norwegian Patent No. 324042 for its lead
immunosuppressive drug, ISA247. Obtaining the patent in Norway completes the
protection over the novel structural features of ISA247 in Europe.
A total of 83 patents worldwide have been issued relating to ISA247's
structure, composition, formulation and methods of synthesis.
"In accordance with our overall strategic plan, we continue to secure
patent protection worldwide in anticipation of acquiring market approval for
ISA247," stated Dr. Robert Foster, Isotechnika's Chairman and Chief Executive
Officer. "This indicates that ISA247 will have exclusivity for at least
another 15 years. Additional claims for ISA247 will be pursued to ensure that
intellectual property is secured in all of the major markets worldwide."
Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential exceeds $2 billion annually in sales for
calcineurin inhibitors such as ISA247.
ISA247 is currently being investigated in a Phase 2b North American trial
for the prevention of kidney graft rejection subsequent to transplantation and
a Phase 3 European/Canadian psoriasis trial.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
Partnerships with Isotechnika Inc.
- Roche retains an option to continue development of the transplant
indications based on the successful completion of the ongoing Phase
2b kidney transplant trial.
- Atrium Medical Corporation has exclusive worldwide licensing
agreement for use of ISA247 and TAFA93 with drug eluting devices for
non-systemic treatment of vascular, cardiovascular, target vessel and
- Lux Biosciences Inc. was granted worldwide rights to develop and
commercialize ISA247 for the treatment and prophylaxis of all
This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.
For further information:
For further information: Dr. Robert Foster, Chairman & CEO, Isotechnika
Inc., Phone: (780) 487-1600 (x247), Fax: (780) 484-4105, E-mail:
firstname.lastname@example.org; Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., Phone: (780) 487-1600 (x243), Fax: (780)
484-4105, E-mail: email@example.com